Cargando…

Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets

SIMPLE SUMMARY: Chronic lymphocytic leukemia harbors a high degree of genetic variability and interpatient heterogeneity. Some of the genetic alterations have an impact on the disease’s prognosis and evolution, but few data exist about the response to new approved targeted therapies in patients carr...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Oreja, Irene, Playa-Albinyana, Heribert, Arenas, Fabián, López-Guerra, Mónica, Colomer, Dolors
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269088/ https://www.ncbi.nlm.nih.gov/pubmed/34202439 http://dx.doi.org/10.3390/cancers13133150

Ejemplares similares

SF3B1 mutation–mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia
por: Gimenez, Neus, et al.
Publicado: (2020)

All-CLL: A Capture-based Next-generation Sequencing Panel for the Molecular Characterization of Chronic Lymphocytic Leukemia
por: López-Oreja, Irene, et al.
Publicado: (2023)

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells
por: López-Guerra, Mónica, et al.
Publicado: (2019)

A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
por: Araujo-Ayala, Ferran, et al.
Publicado: (2023)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Identification by mass spectrometry and immunoblotting of xenogeneic antigens in the N- and O-glycomes of porcine, bovine and equine heart tissues
por: Jin, Chunsheng, et al.
Publicado: (2020)

Targeted therapy in CLL: changing the treatment paradigm
por: Schneider, Christof, et al.
Publicado: (2019)

Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy
por: Silkenstedt, Elisabeth, et al.
Publicado: (2019)

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia
por: Giménez, Neus, et al.
Publicado: (2019)

Targeting CLL-1 for acute myeloid leukemia therapy
por: Ma, Hongbing, et al.
Publicado: (2019)

Novel Tools for Diagnosis and Monitoring of AML
por: Guijarro, Francesca, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing
por: Garrote, Marta, et al.
Publicado: (2023)

Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
por: Cuesta-Mateos, Carlos, et al.
Publicado: (2021)

Pharmacological targeting of eIF4E in primary CLL lymphocytes
por: Martinez-Marignac, V, et al.
Publicado: (2013)

Prediction of clinical outcome in CLL based on recurrent gene mutations, CLL-IPI variables, and (para)clinical data
por: Parviz, Mehdi, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Approval success rates of drug candidates based on target, action, modality, application, and their combinations
por: Yamaguchi, Shingo, et al.
Publicado: (2021)

Targeting ATM-deficient CLL through interference with DNA repair pathways
por: Knittel, Gero, et al.
Publicado: (2015)

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
por: Kwok, Marwan, et al.
Publicado: (2021)

Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
por: Pflug, Natali, et al.
Publicado: (2021)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL
por: Efremov, Dimitar G., et al.
Publicado: (2012)

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
por: Wang, Jinghua, et al.
Publicado: (2018)

P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Huebner, Juwita, et al.
Publicado: (2023)

Rituximab mechanisms of action in B-CLL: a new piece of the puzzle
por: Watier, Hervé
Publicado: (2018)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial
por: Oscier, David, et al.
Publicado: (2016)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis
por: Vassilopoulos, Stephanos, et al.
Publicado: (2022)

The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors
por: Sampietro, Marta, et al.
Publicado: (2023)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Adverse events of targeted therapies approved for women's cancers
por: Saint-Ghislain, Mathilde, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h2b8f31e0k13ecgb92a5mrvion